# Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation

Study · id `cardio:ct-nct07389941` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07389941](<https://clinicaltrials.gov/study/NCT07389941>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07389941

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 240 participants.

## Technical summary

Registry record NCT07389941. Randomized; single masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2029-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT07389941, source copy `cardio:ctgov-nct07389941-2026-02-11`, retrieved 2026-10-26)
- Planned start: 2026-10 (anticipated) (ClinicalTrials.gov record NCT07389941, source copy `cardio:ctgov-nct07389941-2026-02-11`, retrieved 2026-10-26)
- Primary completion: 2029-04 (anticipated) (ClinicalTrials.gov record NCT07389941, source copy `cardio:ctgov-nct07389941-2026-02-11`, retrieved 2026-10-26)
- Completion: 2029-04 (anticipated) (ClinicalTrials.gov record NCT07389941, source copy `cardio:ctgov-nct07389941-2026-02-11`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07389941-2026-02-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation
- Acronym: SPICE-AF
- Condition: Atrial Fibrillation (AF)
- Intervention (Drug): Semaglutide (SEMA)
- Lead sponsor: University of Luebeck
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: University of Luebeck (`cardio:org-university-of-luebeck`)

## Provenance

Content hash: 9a46e3e643eb2e471c8598880dd3d5d7b2e2a9615baf378deb9603061a6dad9e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
